Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Colorcon
Deloitte
Accenture
Julphar
Baxter

Generated: May 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,555,133

« Back to Dashboard

Which drugs does patent 6,555,133 protect, and when does it expire?

Patent 6,555,133 protects SUSTIVA and is included in one NDA.

Protection for SUSTIVA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-five patent family members in twenty-six countries.

Summary for Patent: 6,555,133
Title: Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
Abstract:The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.
Inventor(s): Makooi-Morehead; William T. (Wallingford, PA), Buehler; John D. (Ambler, PA), Landmann; Brian R. (Hoboken, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:09/824,071
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 6,555,133
Patent Claim Types:
see list of patent claims
Use; Dosage form; Formulation; Composition;

Drugs Protected by US Patent 6,555,133

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-001 Sep 17, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-002 Sep 17, 1998 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-003 Sep 17, 1998 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 6,555,133

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 019031 ➤ Sign Up
Austria 223719 ➤ Sign Up
Australia 3463799 ➤ Sign Up
Australia 756422 ➤ Sign Up
Brazil 9908810 ➤ Sign Up
Canada 2321523 ➤ Sign Up
China 1146419 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Accenture
Johnson and Johnson
US Army
Farmers Insurance
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.